NASDAQ:GMDA - Nasdaq - IL0011552663 - Common Stock - Currency: USD
It's time to dive into all of the biggest pre-market stock movers that traders will want to keep an eye on Friday morning!
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly issued a weak outlook. Ulta Beauty shares dipped 13.7% to $448.08 on Wednesday.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Gamida Cell (NASDAQ:GMDA) just reported results for the fourth quarter of 2023....
Gamida Cell shares plummet as the company enters a restructuring agreement with Highbridge Capital Management, aiming to secure long-term financial stability.
Appoints Abigail “Abbey” Jenkins, a veteran biotech executive with over 20 years of experience in commercial leadership, to Board of Directors
Pre-market stock movers are a hot topic on Thursday as we check out all of the biggest stories moving shares this morning!
Trump Media & Technology stock is on the rise Wednesday as shares of DJT continue to rally for the second day after going public.
GMDA stock results show that Gamida Cell beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023.
Reddit stock is a hot topic among traders on Wednesday after one analyst warns that RDDT could give up 50% of its gains.
Gamida Cell stock is falling on Wednesday with heavy trading of GMDA shares after the company announced plans to go private.
Company expected to receive significant new capital from Highbridge to bolster the commercialization of allogeneic stem cell transplant Omisirge®...
Company announces commencement of restructuring process supported by Highbridge Capital Management Continued progress of launch of Omisirge®...
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics,...
Expanded access program (EAP) data for omidubicel are consistent with Phase 3 trial results on rates of hematopoietic recovery and infections following...
Gamida Cell's shares surge 24% as the cell therapy firm explores strategic alternatives such as asset sale or merger.
BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today...
BOSTON, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, is...
BOSTON, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Gamida Cell Ltd. (Nasdaq: GMDA), a cell therapy pioneer working to turn cells into powerful therapeutics, today...
Gamida Cell (NASDAQ:GMDA) on Wednesday filed a prospectus for a mixed securities shelf offering of up to $150M.This prospectus is not an offer to sell these...
Company continues to advance launch, reports initial revenue from Omisirge® (omidubicel-onlv) Company to host conference call today at 8:30 a.m....
Data further characterize the mechanism for Gamida Cell’s proprietary nicotinamide (NAM) technology’s expansion and enhancement of cells...